Unilateral transcranial photobiomodulation for opioid addiction in a clinical practice: A clinical overview and case series

What the authors concluded

The case reports are from 42 consecutive patients in his practice with OUD where he has given 382 treatments over 18 months, as needed. The author's subjective clinical observations were that of the 42 patients, 26 (62%) consistently had responses to the UtPBM (as described in the case reports) that were easily observable to the patient and the author as strikingly beneficial, 8 (19%) had helpful

Devices that emit this wavelength

Matched on wavelength within 15nm, since LED bins vary by roughly that much and a tighter match would be false precision. Where we have an irradiance figure, the session length is the time needed to reach this study's dose of 60 J/cm² at that intensity.

Matching a wavelength is not the same as reproducing a trial. Session times assume the device's published irradiance is accurate at the distance it was measured, which on brand-claim figures is often optimistic. Where a device publishes both a peak and an average we use the average, and where it publishes a falloff curve we use the lowest figure, so these times run long rather than short. Clinical protocols also control for spot size, contact and skin type in ways a home device cannot.